Remsima and Inflectra are the first biosimilar monoclonal antibodies to become available in the UK.
Although common, this condition can have significant psychosocial sequelae. Prompt diagnosis and engagement in long-term therapy are the keys to successful management. By Dr Mansi Rajpopat and Dr Anshoo Sahota
Register or Subscribe to MIMSGPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.
MIMS bulletinsNews and updates straight to your inbox.
Prescribing Update: Fortnightly news bulletin
Alert: Urgent prescribing updates
Spotlight: Disease-themed monthly round-up
Read the latest issue online exclusively on MIMS Learning.
Especially created for prescribing influencers.